Dermisonics, Inc.' Test With Type-2 Diabetics Proves Insulin Isn't Transported Through The Skin When Patch Not Activated By Ultrasound

IRVINE, CA -- (MARKET WIRE) -- October 03, 2006 -- Dermisonics, Inc. (OTCBB: DMSI) (FWB: FQC), a pioneer in the development of painless injection-free ultrasonic transdermal drug-delivery patches and technologies with broad pharmaceutical and consumer applications, announced today that it has completed another important milestone in readying its U-Strip Insulin Patch for regulatory approval. The recently completed HPT-3B human pilot trial successfully demonstrated that conventional passive transdermal patches loaded with insulin would not allow the transfer of insulin through the skin passively. The successful results of this test were significant because they demonstrated that the insulin molecule is too large for passive transdermal transport. In other words, a passive patch will not allow insulin to be absorbed into the body; Dermisonics believes only the U-Strip system, where the insulin-loaded patch is combined with the Company's ultrasound transducer to enlarge the skin pores, has been effective in insulin transdermal delivery.

Back to news